Perfusion and Metabolism Imaging Studies In Parkinson's Disease - With special reference to intensity normalization methods

Danish Medical Journal

Volumn 59, Issue 6, 2012, Pages

  Borghammer, Per ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

1, 2, 3, 6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FLUORODEOXYGLUCOSE F 18; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; AUTORADIOGRAPHY; BRAIN BLOOD FLOW; BRAIN DISEASE; BRAIN PERFUSION; CLUSTER ANALYSIS; DISEASE SIMULATION; GLOBAL CHANGE; GLOBUS PALLIDUS; GLUCOSE METABOLISM; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERMETABOLISM; META ANALYSIS(TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; WHITE MATTER;

EID: 84873259478     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (230)

1. Aarsland, D. & Kurz, M. W. 2010. The epidemiology of dementia associated with Parkinson's disease. Brain Pathology, 20, 633-9.
2. Abe, Y., Kachi, T., Kato, T., Arahata, Y., Yamada, T., Washimi, Y., Iwai, K., et. al. 2003. Occipital hypoperfusion in Parkinson's disease without dementia: correlation to impaired cortical visual processing. J Neurol Neurosurg Psychiatry, 74, 419-22.
3. Agid, Y., Graybiel, A. M., Ruberg, M., Hirsch, E., Blin, J., Dubois, B. & Javoy-Agid, F. 1990. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Adv Neurol, 53, 83-100.
4. Agniel, A., Celsis, P., Viallard, G., Montastruc, J. L., Rascol, O., Demonet, J. F., Marc-Vergnes, J. P. & Rascol, A. 1991. Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries. J" Neurol" Neurosurg" Psychiatry, 54, 783-6.
5. Ahl, B., Weissenborn, K., van den Hoff, J., Fischer-Wasels, D., Kostler, H., Hecker, H. & Burchert, W. 2004. Regional differences in cerebral blood flow and cerebral ammonia metabolism in patients with cirrhosis. Hepatology, 40, 73-9.
6. Alavi, A., Smith, R. & Duncan, D. 1994. What are the sources of error in measuring and calculating cerebral metabolic rates with fluorine-18-fluorodeoxyglucose and PET? J Nucl Med, 35, 1466-70.
7. Alexander, G. E., Crutcher, M. D. & DeLong, M. R. 1990. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res, 85, 119-46.
8. Alexander, G. E., Mentis, M. J., Van Horn, J. D., Grady, C. L., Berman, K. F., Furey, M. L., Pietrini, P., Rapoport, S. I., Schapiro, M. B. Moeller, J. R. 1999. Individual differences in PET activation of object perception and attention systems predict face matching accuracy. Neuroreport, 10, 1965-71.
9. Andersson, J. L. 1997. How to estimate global activity independent of changes in local activity. Neuroimage, 6, 237-44.
10. Antonini, A., De Notaris, R., Benti, R., De Gaspari, D. & Pezzoli, G. 2001. Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson's disease. Neurol Sci, 22, 45-6.
11. Arahata, Y., Hirayama, M., Ieda, T., Koike, Y., Kato, T., Tadokoro, M., Ikeda, M., Ito, K. & Sobue, G. 1999. Parieto-occipital glucose hypometabolism in Parkinson's disease with autonomic failure. J Neurol Sci, 163, 119-26.
12. Arndt, S., Cizadlo, T., O'Leary, D., Gold, S. Andreasen, N. C. 1996. Normalizing counts and cerebral blood flow intensity in functional imaging studies of the human brain. Neuroimage, 3, 175-84.
13. Arndt, S., Cohen, G., Alliger, R. J., Swayze, V. W., 2nd & Andreasen, N. C. 1991. Problems with ratio and proportion measures of imaged cerebral structures. Psychiatry Res, 40, 79-89.
14. Asanuma, K., Ma, Y., Huang, C., Carbon-Correll, M., Edwards, C., Raymond, D., Bressman, S. B., Moeller, J. R. Eidelberg, D. 2005. The metabolic pathology of dopa-responsive dystonia. Ann Neurol, 57, 596-600.
15. Asanuma, K., Tang, C., Ma, Y., Dhawan, V., Mattis, P., Edwards, C., Kaplitt, M. G., Feigin, A. Eidelberg, D. 2006. Network modulation in the treatment of Parkinson's disease. Brain, 129, 2667-78.
16. Ashburner, J. & Friston, K. J. 2000. Voxel-based morphometry-the methods. Neuroimage, 11, 805-21.
17. Ashburner, J., Hutton, C., Frackowiak, R., Johnsrude, I., Price, C. Friston, K. 1998. Identifying global anatomical differences: deformation-based morphometry. Hum Brain Mapp, 6, 348-57.
18. Attwell, D. Iadecola, C. 2002. The neural basis of functional brain imaging signals. Trends Neurosci, 25, 621-5.
19. Bailey, D. L., Townsend, D., Valk, P. E. & Maisey, M. N. 2005. Positron Emission Tomography: Basic Sciences, Springer.
20. Beal, M. F. 2004. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr, 36, 381-6.
21. Ben-Shachar, D., Bonne, O., Chisin, R., Klein, E., Lester, H., Aharon-Peretz, J., Yona, I. Freedman, N. 2007. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: A FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry, 31, 807-13.
22. Berding, G., Odin, P., Brooks, D. J., Nikkhah, G., Matthies, C., Peschel, T., Shing, M., Kolbe, H., van Den Hoff, J., Fricke, H., Dengler, R., Samii, M. & Knapp, W. H. 2001. Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord, 16, 1014-22.
23. Bes, A., Guell, A., Fabre, N., Dupui, P., Victor, G. Geraud, G. 1983. Cerebral blood flow studied by Xenon-133 inhalation technique in parkinsonism: loss of hyperfrontal pattern. J Cereb Blood Flow Metab, 3, 33-7.
24. Beyer, M. K., Janvin, C. C., Larsen, J. P. Aarsland, D. 2007. A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry, 78, 254-9.
25. Bezard, E., Crossman, A. R., Gross, C. E. Brotchie, J. M. 2001. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb J, 15, 1092-4.
26. Biesold, D., Inanami, O., Sato, A. & Sato, Y. 1989. Stimulation of the nucleus basalis of Meynert increases cerebral cortical blood flow in rats. Neurosci Lett, 98, 39-44.
27. Bohnen, N. I., Minoshima, S., Giordani, B., Frey, K. A. Kuhl, D. E. 1999. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology, 52, 541-6.
28. Borghammer, P. 2008. Perfusion and Metabolism PET studies in Parkinson's Disease, Aarhus, Aarhus University Press.
29. Borghammer, P., Aanerud, J. & Gjedde, A. 2009a. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage, 46, 981-8.
30. Borghammer, P., Chakravarty, M., Jonsdottir, K. Y., Sato, N., Matsuda, H., Ito, K., Arahata, Y., Kato, T. Gjedde, A. 2010. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: probably even at early disease stages. Brain Struct Funct, 214, 303-17.
31. Borghammer, P., Cumming, P., Aanerud, J., Forster, S. Gjedde, A. 2009b. Subcortical elevation of metabolism in Parkinson's disease-a critical reappraisal in the context of global mean normalization. Neuroimage, 47, 1514-21.
32. Borghammer, P., Cumming, P., Aanerud, J. Gjedde, A. 2009c. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson's disease. Neuroimage, 45, 249-57.
33. Borghammer, P., Hansen, S. B., Eggers, C., Chakravarty, M., Vang, K., Aanerud, J., Hilker, R., Heiss, W. D., Rodell, A., Munk, O. L., Keator, D. Gjedde, A. 2012. Glucose metabolism in small subcortical structures in Parkinson's disease. Acta Neurologica Scandinavica, 125, 303-310.
34. Borghammer, P., Jonsdottir, K. Y., Cumming, P., Ostergaard, K., Vang, K., Ashkanian, M., Vafaee, M., Iversen, P. Gjedde, A. 2008. Normalization in PET group comparison studies-the importance of a valid reference region. Neuroimage, 40, 529-40.
35. Borghammer, P., Ostergaard, K., Cumming, P., Gjedde, A., Rodell, A., Hall, N. Chakravarty, M. M. 2009d. A deformation-based morphometry study of patients with early-stage Parkinson's disease. European Journal of Neurology.
36. Braak, H., Del Tredici, K., Rub, U., de Vos, R. A., Jansen Steur, E. N. & Braak, E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
37. Brownell, A. L., Canales, K., Chen, Y. I., Jenkins, B. G., Owen, C., Livni, E., Yu, M., Cicchetti, F., Sanchez-Pernaute, R. & Isacson, O. 2003. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage, 20, 1064-75.
38. Buchsbaum, M. S., Buchsbaum, B. R., Hazlett, E. A., Haznedar, M. M., Newmark, R., Tang, C. Y. Hof, P. R. 2007. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry, 164, 1072-81.
39. Buchsbaum, M. S., Wu, J., DeLisi, L. E., Holcomb, H., Kessler, R., Johnson, J., King, A. C., Hazlett, E., Langston, K. Post, R. M. 1986. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord, 10, 137-52.
40. Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M. & Kopin, I. J. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A, 80, 4546-50.
41. Burton, E. J., McKeith, I. G., Burn, D. J., Williams, E. D. & O'Brien, J. T. 2004. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 127, 791800.
42. Buzsaki, G., Kaila, K. & Raichle, M. 2007. Inhibition and brain work. Neuron, 56, 77183.
43. Camicioli, R., Moore, M. M., Kinney, A., Corbridge, E., Glassberg, K. Kaye, J. A. 2003. Parkinson's disease is associated with hippocampal atrophy. Mov Disord, 18, 784-90.
44. Cannon, J. R. Greenamyre, J. T. 2010. Neurotoxic in vivo models of Parkinson's disease recent advances. Prog Brain Res, 184, 17-33.
45. Carbon, M., Ghilardi, M. F., Feigin, A., Fukuda, M., Silvestri, G., Mentis, M. J., Ghez, C., Moeller, J. R. & Eidelberg, D. 2003. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp, 19, 197-211.
46. Carlson, J. D., Pearlstein, R. D., Buchholz, J., Iacono, R. P. & Maeda, G. 1999. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's model rats. Brain Res, 828, 12-9.
47. Casteels, C., Lauwers, E., Bormans, G., Baekelandt, V. Van Laere, K. 2007. Metabolic-dopaminergic mapping of the 6-hydroxydopamine rat model for Parkinson's disease. Eur J Nucl Med Mol Imaging.
48. Chan-Palay, V. 1988. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. Journal of Comparative Neurology, 273, 543-57.
49. Choo, I. H., Lee, D. Y., Youn, J. C., Jhoo, J. H., Kim, K. W., Lee, D. S., Lee, J. S. & Woo, J. I. 2007. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis Assoc Disord, 21, 77-84.
50. Cudennec, A., Bonvento, G., Duverger, D., Lacombe, P., Seylaz, J. MacKenzie, E. T. 1993. Effects of dorsal raphe nucleus stimulation on cerebral blood flow and flow-metabolism coupling in the conscious rat. Neuroscience, 55, 395-401.
51. Dagher, A. & Nagano-Saito, A. 2007. Functional and anatomical magnetic resonance imaging in Parkinson's disease. Mol Imaging Biol, 9, 234-42.
52. Dalaker, T. O., Zivadinov, R., Ramasamy, D. P., Beyer, M. K., Alves, G., Bronnick, K. S., Tysnes, O. B., Aarsland, D. Larsen, J. P. 2011. Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord, 26, 297301.
53. Damier, P., Hirsch, E. C., Agid, Y. & Graybiel, A. M. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122 (P 8), 1437-48.
54. Dauvilliers, Y., Comte, F., Bayard, S., Carlander, B., Zanca, M. Touchon, J. 2010. A brain PET study in patients with narcolepsy-cataplexy. J Neurol Neurosurg Psychiatry, 81, 344-8.
55. de Jong, H. W., van Velden, F. H., Kloet, R. W., Buijs, F. L., Boellaard, R. Lammertsma, A. A. 2007. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Physics in Medicine and Biology, 52, 1505-26.
56. Defebvre, L., Lecouffe, P., Destee, A., Houdart, P. Steinling, M. 1995. Tomographic measurements of regional cerebral blood flow in progressive supranuclear palsy and Parkinson's disease. Acta NeurolScand, 92, 235-41.
57. Derejko, M., Slawek, J., Wieczorek, D., Brockhuis, B., Dubaniewicz, M. & Lass, P. 2006. Regional cerebral blood flow in Parkinson's disease as an indicator of cognitive impairment. Nucl Med Commun, 27, 945-51.
58. Desco, M., Gispert, J. D., Reig, S., Sanz, J., Pascau, J., Sarramea, F., Benito, C., Santos, A., Palomo, T. & Molina, V. 2003. Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Res, 122, 125-35.
59. Di Chiro, G. Brooks, R. A. 1988. PET quantitation: blessing and curse. J Nucl Med, 29, 1603-4.
60. Diamant, M., Harms, M. P., Immink, R. V., Van Lieshout, J. J. Van Montfrans, G. A. 2002. Twenty-four-hour non-invasive monitoring of systemic haemodynamics and cerebral blood flow velocity in healthy humans. Acta Physiol Scand, 175, 19.
61. Doty, R. L., Stern, M. B., Pfeiffer, C., Gollomp, S. M. Hurtig, H. I. 1992. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 55, 138-42.
62. Dubois, A., Herard, A. S., Delatour, B., Hantraye, P., Bonvento, G., Dhenain, M. Delzescaux, T. 2010. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage, 51, 586-98.
63. Eberling, J. L., Richardson, B. C., Reed, B. R., Wolfe, N. & Jagust, W. J. 1994. Cortical glucose metabolism in Parkinson's disease without dementia. Neurobiol Aging, 15, 329-35.
64. Eckert, T., Barnes, A., Dhawan, V., Frucht, S., Gordon, M. F., Feigin, A. S. Eidelberg, D. 2005. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage, 26, 912-21.
65. Eckert, T., Van Laere, K., Tang, C., Lewis, D. E., Edwards, C., Santens, P. Eidelberg, D. 2007. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging, 34, 496-501.
66. Eggers, C., Hilker, R., Burghaus, L., Schumacher, B. Heiss, W. D. 2009. High resolution positron emission tomography demonstrates basal ganglia dysfunction in early Parkinson's disease. J Neurol Sci, 276, 27-30.
67. Eidelberg, D., Moeller, J. R., Antonini, A., Kazumata, K., Nakamura, T., Dhawan, V., Spetsieris, P., deLeon, D., Bressman, S. B. & Fahn, S. 1998. Functional brain networks in DYT1 dystonia. Ann Neurol, 44, 303-12.
68. Eidelberg, D., Moeller, J. R., Dhawan, V., Sidtis, J. J., Ginos, J. Z., Strother, S. C., Cedarbaum, J., Greene, P., Fahn, S. & Rottenberg, D. A. 1990. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord, 5, 203-13.
69. Eidelberg, D., Moeller, J. R., Dhawan, V., Spetsieris, P., Takikawa, S., Ishikawa, T., Chaly, T., Robeson, W., Margouleff, D., Przedborski, S. et al. 1994. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab, 14, 783-801.
70. Engler, H., Lundberg, P. O., Ekbom, K., Nennesmo, I., Nilsson, A., Bergstrom, M., Tsukada, H., Hartvig, P. Langstrom, B. 2003. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging,30, 85-95.
71. Feigin, A., Antonini, A., Fukuda, M., De Notaris, R., Benti, R., Pezzoli, G., Mentis, M. J., Moeller, J. R. & Eidelberg, D. 2002. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord, 17, 1265-70.
72. Feigin, A., Fukuda, M., Dhawan, V., Przedborski, S., Jackson-Lewis, V., Mentis, M. J., Moeller, J. R. Eidelberg, D. 2001. Metabolic correlates of levodopa response in Parkinson's disease. Neurology, 57, 2083-8.
73. Feigin, A., Tang, C., Ma, Y., Mattis, P., Zgaljardic, D., Guttman, M., Paulsen, J. S., Dhawan, V. Eidelberg, D. 2007. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain, 130, 2858-67.
74. Firbank, M. J., Colloby, S. J., Burn, D. J., McKeith, I. G. & O'Brien, J. T. 2003. Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage, 20, 1309-19.
75. Firbank, M. J., He, J., Blamire, A. M., Singh, B., Danson, P., Kalaria, R. N. & O'Brien, J. T. 2011. Cerebral blood flow by arterial spin labeling in poststroke dementia. Neurology, 76, 1478-84.
76. Fox, P. T., Mintun, M. A., Reiman, E. M. Raichle, M. E. 1988. Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb Blood Flow Metab, 8, 642-53.
77. Frisina, P. G., Haroutunian, V. Libow, L. S. 2009. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord, 15, 144-8.
78. Friston, K. J., Frith, C. D., Liddle, P. F., Dolan, R. J., Lammertsma, A. A. & Frackowiak, R. S. 1990. The relationship between global and local changes in PET scans. J Cereb Blood Flow Metab, 10, 458-66.
79. Frucht, S. J., Trost, M., Ma, Y. & Eidelberg, D. 2004. The metabolic topography of posthypoxic myoclonus. Neurology, 62, 1879-81.
80. Fukuda, M., Mentis, M. J., Ma, Y., Dhawan, V., Antonini, A., Lang, A. E., Lozano, A. M., Hammerstad, J., Lyons, K., Koller, W. C., Moeller, J. R. & Eidelberg, D. 2001. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain, 124, 1601-9.
81. Fukuyama, H., Ogawa, M., Yamauchi, H., Yamaguchi, S., Kimura, J., Yonekura, Y. Konishi, J. 1994. Altered cerebral energy metabolism in Alzheimer's disease: a PET study. J Nucl Med, 35, 1-6.
82. Gai, W. P., Halliday, G. M., Blumbergs, P. C., Geffen, L. B. & Blessing, W. W. 1991. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain, 114 (Pt 5), 2253-67.
83. German, D. C., Manaye, K. F., White, C. L., 3rd, Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N. & Mann, D. M. 1992. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol, 32, 667-76.
84. Ghaemi, M., Raethjen, J., Hilker, R., Rudolf, J., Sobesky, J., Deuschl, G. Heiss, W. D. 2002. Monosymptomatic resting tremor and Parkinson's disease: a multitracer positron emission tomographic study. Mov Disord, 17, 782-8.
85. Gjedde, A., Marrett, S. & Vafaee, M. 2002. Oxidative and nonoxidative metabolism of excited neurons and astrocytes. J Cereb Blood Flow Metab, 22, 1-14.
86. Globus, M., Mildworf, B. Melamed, E. 1985. Cerebral blood flow and cognitive impairment in Parkinson's disease. Neurology, 35, 1135-9.
87. Gnanalingham, K. K., Milkowski, N. A., Smith, L. A., Hunter, A. J., Jenner, P. Marsden, C. D. 1995. Short and long-term changes in cerebral [14C]-2-deoxyglucose uptake in the MPTP-treated marmoset: relationship to locomotor activity. J Neural Transm Gen Sect, 101, 65-82.
88. Gullion, C. M., Devous, M. D., Sr. Rush, A. J. 1996. Effects of four normalizing methods on data analytic results in functional brain imaging. Biol Psychiatry, 40, 1106-21.
89. Habeck, C., Foster, N. L., Perneczky, R., Kurz, A., Alexopoulos, P., Koeppe, R. A., Drzezga, A. Stern, Y. 2008. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage, 40, 1503-15.
90. Habeck, C., Krakauer, J. W., Ghez, C., Sackeim, H. A., Eidelberg, D., Stern, Y. & Moeller, J. R. 2005. A new approach to spatial covariance modeling of functional brain imaging data: ordinal trend analysis. Neural Comput, 17, 160245.
91. Habeck, C. G. 2010. Basics of multivariate analysis in neuroimaging data. J Vis Exp, July 24;(41), pii: 1988.
92. Herholz, K. 2010. Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease. Expert Rev Neurother, 10, 1667-73.
93. Hirsch, E. C., Graybiel, A. M., Duyckaerts, C. & Javoy-Agid, F. 1987. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A, 84, 5976-80.
94. Hoffman, E. J., Huang, S. C. & Phelps, M. E. 1979. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr, 3, 299308.
95. Hosey, L. A., Thompson, J. L., Metman, L. V., van den Munckhof, P. Braun, A. R. 2005. Temporal dynamics of cortical and subcortical responses to apomorphine in Parkinson disease: an H2(15)O PET study. Clin Neuropharmacol, 28, 18-27.
96. Hosokai, Y., Nishio, Y., Hirayama, K., Takeda, A., Ishioka, T., Sawada, Y., Suzuki, K., Itoyama, Y., Takahashi, S., Fukuda, H. Mori, E. 2009. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord, 24, 854-62.
97. Hu, M. T., Taylor-Robinson, S. D., Chaudhuri, K. R., Bell, J. D., Labbe, C., Cunningham, V. J., Koepp, M. J., Hammers, A., Morris, R. G., Turjanski, N. & Brooks, D. J. 2000. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain, 123 (Pt 2), 340-52.
98. Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V. Eidelberg, D. 2007. Changes in network activity with the progression of Parkinson's disease. Brain, 130, 1834-46.
99. Hutchins, G. D., Holden, J. E., Koeppe, R. A., Halama, J. R., Gatley, S. J. & Nickles, R. J. 1984. Alternative approach to single-scan estimation of cerebral glucose metabolic rate using glucose analogs, with particular application to ischemia. J Cereb Blood Flow Metab, 4, 35-40.
100. Hutchinson, M., Nakamura, T., Moeller, J. R., Antonini, A., Belakhlef, A., Dhawan, V. Eidelberg, D. 2000. The metabolic topography of essential blepharospasm: a focal dystonia with general implications. Neurology, 55, 673-7.
101. Ibaraki, M., Shinohara, Y., Nakamura, K., Miura, S., Kinoshita, F. & Kinoshita, T. 2010. Interindividual variations of cerebral blood flow, oxygen delivery, and metabolism in relation to hemoglobin concentration measured by positron emission tomography in humans. J Cereb Blood Flow Metab, 30, 1296-305.
102. Imon, Y., Matsuda, H., Ogawa, M., Kogure, D. Sunohara, N. 1999. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med, 40, 1583-9.
103. Jagust, W. J., Reed, B. R., Martin, E. M., Eberling, J. L. & Nelson-Abbott, R. A. 1992. Cognitive function and regional cerebral blood flow in Parkinson's disease. Brain, 115 (Pt 2), 521-37.
104. Jellinger, K. 1988. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry, 51, 540-3.
105. Jellinger, K. A. 1991. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Molecular and Chemical Neuropathology, 14, 153-97.
106. Jellinger, K. A. 2000. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl, 59, 185-212.
107. Jellinger, K. A. 2008. A critical reappraisal of current staging of Lewy-related pathology in human brain. Acta Neuropathol, 116, 1-16.
108. Jellinger, K. A. & Paulus, W. 1992. Clinico-pathological correlations in Parkinson's disease. Clinical Neurology and Neurosurgery, 94 Suppl, S86-8.
109. Jokinen, P., Scheinin, N., Aalto, S., Nagren, K., Savisto, N., Parkkola, R., Rokka, J., Haaparanta, M., Roytta, M. & Rinne, J. O. 2010. [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord, 16, 666-70.
110. Kalpouzos, G., Chetelat, G., Baron, J. C., Landeau, B., Mevel, K., Godeau, C., Barre, L., Constans, J. M., Viader, F., Eustache, F. & Desgranges, B. 2007. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging.
111. Kalpouzos, G., Chetelat, G., Baron, J. C., Landeau, B., Mevel, K., Godeau, C., Barre, L., Constans, J. M., Viader, F., Eustache, F. & Desgranges, B. 2009. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. NeurobiolAging, 30, 112-24.
112. Kapitan, M., Ferrando, R., Dieguez, E., de Medina, O., Aljanati, R., Ventura, R., Amorin, I., Salinas, D., Langhain, M., Gioia, A., Cardoso, A., Lago, G. Buzo, R. 2009. [Regional cerebral blood flow changes in Parkinson's disease: correlation with disease duration]. Revista Espanola de Medicina Nuclear, 28, 114-20.
113. Karbe, H., Holthoff, V., Huber, M., Herholz, K., Wienhard, K., Wagner, R. Heiss, W. D. 1992. Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm Park Dis Dement Sect, 4, 121-30.
114. Kasama, S., Tachibana, H., Kawabata, K. Yoshikawa, H. 2005. Cerebral blood flow in Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease according to three-dimensional stereotactic surface projection imaging. Dement Geriatr Cogn Disord, 19, 266-75.
115. Kawabata, K., Tachibana, H. Sugita, M. 1991. Cerebral blood flow and dementia in Parkinson's disease. J Geriatr Psychiatry Neurol, 4, 194-203.
116. Kehagia, A. A., Barker, R. A. Robbins, T. W. 2010. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol, 9, 1200-13.
117. Kikuchi, A., Takeda, A., Kimpara, T., Nakagawa, M., Kawashima, R., Sugiura, M., Kinomura, S., Fukuda, H., Chida, K., Okita, N., Takase, S. Itoyama, Y. 2001. Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci, 193, 29-36.
118. Kitamura, S., Ujike, T., Kuroki, S., Sakamoto, S., Soeda, T., Iio, M. & Terashi, A. 1988. [Cerebral blood flow and oxygen metabolism in patients with Parkinson's disease]. No To Shinkei, 40, 979-85.
119. Kondo, S., Tanaka, M., Sun, X., Okamoto, K. & Hirai, S. 1994. [Cerebral blood flow and oxygen metabolism in patients with pure akinesia and progressive supranuclear palsy]. Rinsho Shinkeigaku, 34, 531-7.
120. Kosaka, K., Tsuchiya, K. Yoshimura, M. 1988. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clinical Neuropathology, 7, 299-305.
121. Kozlowski, M. R. & Marshall, J. F. 1980. Plasticity of [14C]2-deoxy-D-glucose incorporation into neostriatum and related structures in response to dopamine neuron damage and apomorphine replacement. Brain Res, 197, 167-83.
122. Kozlowski, M. R. Marshall, J. F. 1983. Recovery of function and basal ganglia [14C]2-deoxyglucose uptake after nigrostriatal injury. Brain Res, 259, 237-48.
123. Kuhl, D. E., Metter, E. J. Riege, W. H. 1984. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol, 15, 419-24.
124. Lacombe, P., Sercombe, R., Verrecchia, C., Philipson, V., MacKenzie, E. T. Seylaz, J. 1989. Cortical blood flow increases induced by stimulation of the substantia innominata in the unanesthetized rat. Brain Res, 491, 1-14.
125. Langston, J. W. 2006. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol, 59, 591-6.
126. Leenders, K. L., Perani, D., Lammertsma, A. A., Heather, J. D., Buckingham, P., Healy, M. J., Gibbs, J. M., Wise, R. J., Hatazawa, J., Herold, S. et al. 1990. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain, 113 (Pt 1), 27-47.
127. Leenders, K. L., Wolfson, L., Gibbs, J. M., Wise, R. J., Causon, R., Jones, T. Legg, N. J. 1985. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain, 108 (Pt 1), 171-91.
128. Lockwood, A. H., Yap, E. W., Rhoades, H. M. Wong, W. H. 1991. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab, 11, 331-6.
129. Lozza, C., Baron, J. C., Eidelberg, D., Mentis, M. J., Carbon, M. & Marie, R. M. 2004. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp, 22, 236-45.
130. Ma, Y., Tang, C., Moeller, J. R. Eidelberg, D. 2009. Abnormal regional brain function in Parkinson's disease: truth or fiction? Neuroimage, 45, 260-6.
131. Ma, Y., Tang, C., Spetsieris, P. G., Dhawan, V. Eidelberg, D. 2007. Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. J Cereb Blood Flow Metab, 27, 597-605.
132. Markus, H. S., Costa, D. C. & Lees, A. J. 1994. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness. J Neurol Neurosurg Psychiatry, 57, 180-5.
133. Markus, H. S., Lees, A. J., Lennox, G., Marsden, C. D. & Costa, D. C. 1995. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls. Mov Disord, 10, 179-87.
134. Matsui, H., Udaka, F., Miyoshi, T., Hara, N., Tamura, A., Oda, M., Kubori, T., Nishinaka, K. Kameyama, M. 2005. Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features. Parkinsonism Relat Disord, 11, 227-32.
135. Mattila, P. M., Roytta, M., Lonnberg, P., Marjamaki, P., Helenius, H. Rinne, J. O. 2001. Choline acetytransferase activity and striatal dopamine receptors in Parkinson's disease in relation to cognitive impairment. Acta Neuropathol, 102, 160-6.
136. McNaught, K. S. Olanow, C. W. 2006. Protein aggregation in the pathogenesis of familial and sporadic Parkinson's disease. NeurobiolAging, 27, 530-45.
137. Meissner, W., Guigoni, C., Cirilli, L., Garret, M., Bioulac, B. H., Gross, C. E., Bezard, E. & Benazzouz, A. 2007. Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. Eur J Neurosci, 25, 1492-500.
138. Meltzer, C. C., Cantwell, M. N., Greer, P. J., Ben-Eliezer, D., Smith, G., Frank, G., Kaye, W. H., Houck, P. R. Price, J. C. 2000. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med, 41, 1842-8.
139. Melzer, T. R., Watts, R., Macaskill, M. R., Pearson, J. F., Rueger, S., Pitcher, T. L., Livingston, L., Graham, C., Keenan, R., Shankaranarayanan, A., Alsop, D. C., Dalrymple-Alford, J. C. & Anderson, T. J. 2011. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain, 134(Pt 3), 845-55.
140. Mentis, M. J., McIntosh, A. R., Perrine, K., Dhawan, V., Berlin, B., Feigin, A., Edwards, C., Mattis, P. Eidelberg, D. 2002. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry, 159, 746-54.
141. Miletich, R. S., Quarantelli, M. Di Chiro, G. 1994. Regional cerebral blood flow imaging with 99mTc-bicisate SPECT in asymmetric Parkinson's disease: studies with and without chronic drug therapy. J Cereb Blood Flow Metab, 14 Suppl 1, S106-14.
142. Mink, J. W. 2003. The Basal Ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol, 60, 1365-8.
143. Minoshima, S., Frey, K. A., Foster, N. L. Kuhl, D. E. 1995. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr, 19, 541-7.
144. Mitchell, I. J., Boyce, S., Sambrook, M. A. & Crossman, A. R. 1992. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain, 115 (Pt 3), 809-24.
145. Mitchell, I. J., Clarke, C. E., Boyce, S., Robertson, R. G., Peggs, D., Sambrook, M. A. & Crossman, A. R. 1989. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience, 32, 213-26.
146. Mitchell, I. J., Cross, A. J., Sambrook, M. A. Crossman, A. R. 1986. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neurosci Lett, 63, 61-5.
147. Mito, Y., Yoshida, K., Yabe, I., Makino, K., Hirotani, M., Tashiro, K., Kikuchi, S. & Sasaki, H. 2005. Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease. Clinical Neurology and Neurosurgery, 107, 396-403.
148. Miyazawa, N., Shinohara, T., Nagasaka, T. Hayashi, M. 2010. Hypermetabolism in patients with dementia with Lewy bodies. Clinical Nuclear Medicine, 35, 490-3.
149. Moeller, J. R., Ishikawa, T., Dhawan, V., Spetsieris, P., Mandel, F., Alexander, G. E., Grady, C., Pietrini, P. Eidelberg, D. 1996. The metabolic topography of normal aging. J Cereb Blood Flow Metab, 16, 385-98.
150. Moeller, J. R., Nakamura, T., Mentis, M. J., Dhawan, V., Spetsieres, P., Antonini, A., Missimer, J., Leenders, K. L. et. al. 1999. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med, 40, 1264-9.
151. Moeller, J. R., Strother, S. C., Sidtis, J. J. Rottenberg, D. A. 1987. Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab, T, 649-58.
152. Montastruc, J. L., Celsis, P., Agniel, A., Demonet, J. F., Doyon, B., Puel, M., Marc-Vergnes, J. P. & Rascol, A. 1987. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements. Mov Disord, 2, 279-89.
153. Mraovitch, S., Calando, Y., Onteniente, B., Peschanski, M. Seylaz, J. 1993. Cerebrovascular and metabolic uncoupling in the caudate-putamen following unilateral lesion of the mesencephalic dopaminergic neurons in the rat. Neurosci Lett, 157, 140-4.
154. Nagano-Saito, A., Kato, T., Arahata, Y., Washimi, Y., Nakamura, A., Abe, Y., Yamada, T., Iwai, K., Hatano, K., Kawasumi, Y., Kachi, T., Dagher, A. & Ito, K. 2004a. Cognitive-and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies. Neuroimage, 22, 553-61.
155. Nagano-Saito, A., Washimi, Y., Arahata, Y., Iwai, K., Kawatsu, S., Ito, K., Nakamura, A., Abe, Y., Yamada, T., Kato, T. Kachi, T. 2004b. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord, 19, 801-6.
156. Nagano-Saito, A., Washimi, Y., Arahata, Y., Kachi, T., Lerch, J. P., Evans, A. C., Dagher, A. Ito, K. 2005. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology, 64, 224-9.
157. Nicholson, R. M., Kusne, Y., Nowak, L. A., LaFerla, F. M., Reiman, E. M. Valla, J. 2010. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res, 1347, 179-85.
158. O'Carroll, R. E., Hayes, P. C., Ebmeier, K. P., Dougall, N., Murray, C., Best, J. J., Bouchier, I. A. Goodwin, G. M. 1991. Regional cerebral blood flow and cognitive function in patients with chronic liver disease. Lancet, 337, 1250-3.
159. Obeso, J. A., Marin, C., Rodriguez-Oroz, C., Blesa, J., Benitez-Temino, B., Mena-Segovia, J., Rodriguez, M. Olanow, C. W. 2008. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol, 64 Suppl 2, S30-46.
160. Osaki, Y., Morita, Y., Fukumoto, M., Akagi, N., Yoshida, S. & Doi, Y. 2005. Threedimensional stereotactic surface projection SPECT analysis in Parkinson's disease with and without dementia. Mov Disord, 20, 999-1005.
161. Otsuka, M., Ichiya, Y., Hosokawa, S., Kuwabara, Y., Tahara, T., Fukumura, T., Kato, M., Masuda, K. & Goto, I. 1991. Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry, 54, 898-904.
162. Otsuka, M., Ichiya, Y., Kuwabara, Y., Hosokawa, S., Sasaki, M., Yoshida, T., Fukumura, T., Kato, M. Masuda, K. 1996. Glucose metabolism in the cortical and subcortical brain structures in multiple system atrophy and Parkinson's disease: a positron emission tomographic study. J Neurol Sci, 144, 77-83.
163. Palombo, E., Porrino, L. J., Bankiewicz, K. S., Crane, A. M., Sokoloff, L. Kopin, I. J. 1990. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci, 10, 860-9.
164. Palombo, E., Porrino, L. J., Crane, A. M., Bankiewicz, K. S., Kopin, I. J. Sokoloff, L. 1991. Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys. J Neurochem, 56, 1639-46.
165. Parkinson, J. 1817. An essay on the shaking palsy., London, Whittingham and Rowland.
166. Peppard, R. F., Martin, W. R., Carr, G. D., Grochowski, E., Schulzer, M., Guttman, M., McGeer, P. L., Phillips, A. G., Tsui, J. K. Calne, D. B. 1992. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol, 49, 1262-8.
167. Peran, P., Cherubini, A., Luccichenti, G., Hagberg, G., Demonet, J. F., Rascol, O., Celsis, P., Caltagirone, C., Spalletta, G. Sabatini, U. 2009. Volume and iron content in basal ganglia and thalamus. Human Brain Mapping, 30, 2667-75.
168. Perico, C. A., Skaf, C. R., Yamada, A., Duran, F., Buchpiguel, C. A., Castro, C. C., Soares, J. C. Busatto, G. F. 2005. Relationship between regional cerebral blood flow and separate symptom clusters of major depression: a single photon emission computed tomography study using statistical parametric mapping. Neuroscience Letters, 384, 265-70.
169. Perlmutter, J. S. Raichle, M. E. 1985. Regional blood flow in hemiparkinsonism. Neurology, 35, 1127-34.
170. Piao, Y. S., Mori, F., Hayashi, S., Tanji, K., Yoshimoto, M., Kakita, A., Wakabayashi, K. & Takahashi, H. 2003. Alpha-synuclein pathology affecting Bergmann glia of the cerebellum in patients with alpha-synucleinopathies. Acta Neuropathol, 105, 403-9.
171. Piert, M., Koeppe, R. A., Giordani, B., Minoshima, S. Kuhl, D. E. 1996. Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med, 37, 1115-22.
172. Pizzolato, G., Dam, M., Borsato, N., Saitta, B., Da Col, C., Perlotto, N., Zanco, P., Ferlin, G. & Battistin, L. 1988. [99mTc]-HM-PAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab, 8, S101-8.
173. Playford, E. D., Jenkins, I. H., Passingham, R. E., Nutt, J., Frackowiak, R. S. Brooks, D. J. 1992. Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol, 32, 151-61.
174. Porrino, L. J., Burns, R. S., Crane, A. M., Palombo, E., Kopin, I. J. & Sokoloff, L. 1987. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate. Life Sci, 40, 1657-64.
175. Poston, K. L. Eidelberg, D. 2010. FDG PET in the Evaluation of Parkinson's Disease. PET Clin, 5, 55-64.
176. Pourfar, M., Feigin, A., Tang, C. C., Carbon-Correll, M., Bussa, M., Budman, C., Dhawan, V. Eidelberg, D. 2011. Abnormal metabolic brain networks in Tourette syndrome. Neurology, 76, 944-52.
177. Powers, W. J., Videen, T. O., Markham, J., Black, K. J., Golchin, N. & Perlmutter, J. S. 2008. Cerebral mitochondrial metabolism in early Parkinson's disease. J Cereb Blood Flow Metab, 28, 1754-60.
178. Ramirez-Ruiz, B., Marti, M. J., Tolosa, E., Bartres-Faz, D., Summerfield, C., Salgado-Pineda, P., Gomez-Anson, B. & Junque, C. 2005. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol, 252, 1345-52.
179. Ramsay, S. C., Murphy, K., Shea, S. A., Friston, K. J., Lammertsma, A. A., Clark, J. C., Adams, L., Guz, A. Frackowiak, R. S. 1993. Changes in global cerebral blood flow in humans: effect on regional cerebral blood flow during a neural activation task. J Physiol, 411, 521-34.
180. Reed, L. J., Lasserson, D., Marsden, P., Stanhope, N., Stevens, T., Bello, F., Kingsley, D., Colchester, A. & Kopelman, M. D. 2003. FDG-PET findings in the Wernicke-Korsakoff syndrome. Cortex, 39, 1027-45.
181. Rottenberg, D. A., Moeller, J. R., Strother, S. C., Sidtis, J. J., Navia, B. A., Dhawan, V., Ginos, J. Z. Price, R. W. 1987. The metabolic pathology of the AIDS dementia complex. Ann Neurol, 22, 700-6.
182. Rougemont, D., Baron, J. C., Collard, P., Bustany, P., Comar, D. & Agid, Y. 1984. Local cerebral glucose utilisation in treated and untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry, 41, 824-30.
183. Rousset, O. G., Ma, Y. Evans, A. C. 1998. Correction for partial volume effects in PET: principle and validation. J Nucl Med, 39, 904-11.
184. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ji, Y., Quartermain, D., Jensen, C. H., Duff, K., Nixon, R. A., Gruen, R. J. & Wisniewski, T. 2004. Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice. Journal of Neuropathology and Experimental Neurology, 63, 418-28.
185. Sagar, S. M. & Snodgrass, S. R. 1980. Effects of substantia nigra lesions on forebrain 2-deoxyglucose retention in the rat. Brain Res, 185, 335-48.
186. Sasaki, M., Ichiya, Y., Hosokawa, S., Otsuka, M., Kuwabara, Y., Fukumura, T., Kato, M., Goto, I. Masuda, K. 1992. Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia. Ann Nucl Med, 6, 241-6.
187. Sawada, H., Udaka, F., Kameyama, M., Seriu, N., Nishinaka, K., Shindou, K., Kodama, M., Nishitani, N. Okumiya, K. 1992. SPECT findings in Parkinson's disease associated with dementia. J Neurol Neurosurg Psychiatry, 55, 960-3.
188. Scarmeas, N., Habeck, C. G., Zarahn, E., Anderson, K. E., Park, A., Hilton, J., Pelton, G. H., Tabert, M. H., Honig, L. S., Moeller, J. R., Devanand, D. P. Stern, Y. 2004. Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage, 23, 35-45.
189. Schapira, A. H. 2009. Neurobiology and treatment of Parkinson's disease. Trends Pharmacol Sci, 30, 41-7.
190. Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B. & Marsden, C. D. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 1, 1269.
191. Schwartz, W. J., Sharp, F. R., Gunn, R. H. & Evarts, E. V. 1976. Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature, 261, 155-7.
192. Schwartzman, R. J. Alexander, G. M. 1985. Changes in the local cerebral metabolic rate for glucose in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) primate model of Parkinson's disease. Brain Res, 358, 137-43.
193. Schwartzman, R. J., Alexander, G. M., Ferraro, T. N., Grothusen, J. R. & Stahl, S. M. 1988. Cerebral metabolism of parkinsonian primates 21 days after MPTP. Exp Neurol, 102, 307-13.
194. Seppi, K. Poewe, W. 2010. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clinics of North America, 20, 29-55.
195. Shimada, H., Hirano, S., Shinotoh, H., Aotsuka, A., Sato, K., Tanaka, N., Ota, T., Asahina, M., Fukushi, K., Kuwabara, S., Hattori, T., Suhara, T. & Irie, T. 2009. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology.
196. Sirotin, Y. B. Das, A. 2009. Anticipatory haemodynamic signals in sensory cortex not predicted by local neuronal activity. Nature, 457, 475-9.
197. Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M. H., Patlak, C. S., Pettigrew, K. D., Sakurada, O. Shinohara, M. 1977. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem, 28, 897-916.
198. Song, S. K., Lee, J. E., Park, H. J., Sohn, Y. H., Lee, J. D. & Lee, P. H. 2011. The pattern of cortical atrophy in patients with Parkinson's disease according to cognitive status. Mov Disord, 26, 289-96.
199. Soonawala, D., Amin, T., Ebmeier, K. P., Steele, J. D., Dougall, N. J., Best, J., Migneco, O., Nobili, F. & Scheidhauer, K. 2002. Statistical parametric mapping of (99m)Tc-HMPAO-SPECT images for the diagnosis of Alzheimer's disease: normalizing to cerebellar tracer uptake. Neuroimage, 17, 1193-202.
200. Spampinato, U., Habert, M. O., Mas, J. L., Bourdel, M. C., Ziegler, M., de Recondo, J., Askienazy, S. & Rondot, P. 1991. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry, 54, 787-92.
201. Spetsieris, P., Ma, Y., Dhawan, V., Moeller, J. R. Eidelberg, D. 2006. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Med Imag, 6144, 5M1-12.
202. Spetsieris, P. G., Ma, Y., Dhawan, V. Eidelberg, D. 2009. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage, 45, 1241-52.
203. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R. Goedert, M. 1997. Alpha-synuclein in Lewy bodies. Nature, 388, 839-40.
204. Strother, S. C., Anderson, J. R., Schaper, K. A., Sidtis, J. J., et al. 1995. Principal component analysis and the scaled subprofile model compared to intersubject averaging and statistical parametric mapping: I. "Functional connectivity" of the human motor system studied with [15O]water PET. J Cereb Blood Flow Metab, 15, 738-53.
205. Sudarsky, L., Morris, J., Romero, J. & Walshe, T. M. 1989. Dementia in Parkinson's disease: the problem of clinicopathological correlation. Journal of Neuropsychiatry and Clinical Neurosciences, 1, 159-66.
206. Summerfield, C., Junque, C., Tolosa, E., Salgado-Pineda, P., Gomez-Anson, B., Marti, M. J., Pastor, P., Ramirez-Ruiz, B. & Mercader, J. 2005. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol, 62, 281-5.
207. Tachibana, H., Tomino, Y., Kawabata, K., Sugita, M. & Fukuchi, M. 1995. Twelvemonth follow-up study of regional cerebral blood flow in Parkinson's disease. Dementia, 6, 89-93.
208. Talairach, J. & Tournoux, P. 1988. Co-planar stereotaxic atlas of the human brain., New York, Thieme Verlag.
209. Tam, C. W., Burton, E. J., McKeith, I. G., Burn, D. J. O'Brien, J. T. 2005. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology, 64, 861-5.
210. Tinaz, S., Courtney, M. G. Stern, C. E. 2011. Focal cortical and subcortical atrophy in early Parkinson's disease. Mov Disord, 26, 436-41.
211. Trost, M., Carbon, M., Edwards, C., Ma, Y., Raymond, D., Mentis, M. J., Moeller, J. R., Bressman, S. B. Eidelberg, D. 2002. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol, 52, 853-6.
212. Trost, M., Su, S., Su, P., Yen, R. F., Tseng, H. M., Barnes, A., Ma, Y. Eidelberg, D. 2006. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage, 31, 301-7.
213. Trugman, J. M. & Wooten, G. F. 1986. The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra. Brain Res, 379, 264-74.
214. Uhl, G. R., Hedreen, J. C. Price, D. L. 1985. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology, 35, 1215-8.
215. Underwood, M. D., Bakalian, M. J., Arango, V. & Mann, J. J. 1995. Effect of chemical stimulation of the dorsal raphe nucleus on cerebral blood flow in rat. Neurosci Lett, 199, 228-30.
216. Uretsky, N. J. & Iversen, L. L. 1970. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J Neurochem, 17, 269-78.
217. Valk, P. E., Bailey, D. L., Townsend, D. W. & Maisey, M. N. 2003. Positron Emission Tomography-Basic Science and Clinical Applications, London, Springer.
218. Van Laere, K., Santens, P., Bosman, T., De Reuck, J., Mortelmans, L. Dierckx, R. 2004. Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: correlation with clinical parameters. J Nucl Med, 45, 93342.
219. Vander Borght, T., Minoshima, S., Giordani, B., Foster, N. L., Frey, K. A., Berent, S., Albin, R. L., Koeppe, R. A. Kuhl, D. E. 1997. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med, 38, 797-802.
220. Wang, G. J., Volkow, N. D., Wolf, A. P., Brodie, J. D. & Hitzemann, R. J. 1994. Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med, 35, 1457-66.
221. Wang, S. J., Liu, R. S., Liu, H. C., Lin, K. N., Shan, D. E., Liao, K. K., Fuh, J. L. Lee, L. S. 1993. Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization. Eur J Nucl Med, 20, 339-44.
222. Williams, D. S., Detre, J. A., Leigh, J. S. Koretsky, A. P. 1992. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci U S A, 89, 212-6.
223. Wisniewski, T. Sigurdsson, E. M. 2010. Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochimica et Biophysica Acta, 1802, 847-59.
224. Wolfson, L. I., Leenders, K. L., Brown, L. L. & Jones, T. 1985. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology, 35, 1399-405.
225. Wooten, G. F. Collins, R. C. 1981. Metabolic effects of unilateral lesion of the substantia nigra. J Neurosci, 1, 285-91.
226. Wooten, G. F. Collins, R. C. 1983. Effects of dopaminergic stimulation on functional brain metabolism in rats with unilateral substantia nigra lesions. Brain Res, 263, 267-75.
227. Yakushev, I., Hammers, A., Fellgiebel, A., Schmidtmann, I., Scheurich, A., Buchholz, H. G., Peters, J., Bartenstein, P., Lieb, K. & Schreckenberger, M. 2009. SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging. Neuroimage, 44, 43-50.
228. Yanase, D., Matsunari, I., Yajima, K., Chen, W., Fujikawa, A., Nishimura, S., Matsuda, H. Yamada, M. 2005. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging, 32, 794-805.
229. Yoshimura, M. 1988. Pathological basis for dementia in elderly patients with idiopathic Parkinson's disease. European Neurology, 28 Suppl 1, 29-35.
230. Zarow, C., Lyness, S. A., Mortimer, J. A. & Chui, H. C. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol, 60, 337-41.